Bimatoprost (Lumigan)

07/01/2009 - "Bimatoprost was effective and safe in lowering IOP both in open angle and pseudoexfoliative glaucoma, achieving target pressure in most patients. "
01/01/2023 - "This retrospective study found a statistically significant reduction in mean intraocular pressure (IOP) and the number of medications after intracameral Bimatoprost sustained release (SR) injection in patients with glaucoma. "
01/01/2022 - "Significant reduction in IOP could be seen after switching from bimatoprost 0.01% to bimatoprost 0.03% in various types of glaucoma except SOAG. "
09/01/2013 - "Estimate the long-term direct medical costs and clinical consequences of improved adherence with bimatoprost 0.01% compared to bimatoprost 0.03% in the treatment of glaucoma. "
11/17/2022 - "This study hypothesized that a pharmacokinetic-pharmacodynamic (PK-PD) mathematical model developed based on dog studies can be applied to the human eye of different ages, based on physiological parameter adjustment, to predict drug concentrations and effects in response to a new 6-month slow-release, intracameral, intraocular pressure (IOP) lowering, anti-glaucoma bimatoprost implant. "

11/01/2009 - "Pharmacoeconomic data indicate that bimatoprost is cost effective in the treatment of open-angle glaucoma."
07/01/2009 - "A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma."
03/01/2022 - "This longitudinal case-control study included 18 patients with newly diagnosed primary open-angle glaucoma who received topical bimatoprost as a first-line treatment and 20 healthy individuals (age and sex-matched controls). "
06/05/2020 - "Efficacy of bimatoprost for the treatment of primary open-angle glaucoma: A protocol of systematic review and meta-analysis."
01/01/2018 - "[Hypotensive efficacy of bimatoprost in monotherapy of primary open-angle glaucoma]."

02/01/2007 - "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension."
02/25/2014 - "Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients."
09/01/2005 - "The authors concluded that bimatoprost is an effective, well-tolerated treatment for lowering intraocular pressure in Thai patients with open-angle glaucoma or ocular hypertension."
09/15/2016 - "In randomized, controlled trials of open-angle glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %. "
11/01/2004 - "In an open-label 12-week study, the safety and efficacy of bimatoprost 0.03% was evaluated in 55 patients with open-angle glaucoma or ocular hypertension inadequately controlled by topical beta-blocker monotherapy. "

04/01/2014 - "All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (P < 0.05) and in comparison with bimatoprost 0.03% (P < 0.05). "
04/01/2010 - "Bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia. "
12/06/2010 - "Bimatoprost 0.01% was noninferior to vehicle with respect to conjunctival hyperemia in this study population. "
01/01/2005 - "These studies suggest that conjunctival hyperemia, a side effect of bimatoprost treatment, results from non-inflammatory, pharmacologically based vasodilatation."
08/01/2004 - "Conjunctival hyperemia associated with bimatoprost use: a histopathologic study."

04/01/2014 - "Bimatoprost 0.03% was shown to be effective and safe in these studies of Japanese subjects with eyelash hypotrichosis. "
05/01/2016 - "Bimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis."
03/01/2020 - "Both 0.01% and 0.03% bimatoprost are effective and safe for the treatment of eyebrow hypotrichosis. "
01/01/2018 - "The efficacy of bimatoprost for the treatment of eyebrow hypotrichosis has been supported by well-controlled studies. "
05/01/2016 - "Evaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis. "